US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Vita Life Sciences Ltd
ASX:VLS
Vita Life Sciences Ltd
Income from Continuing Operations
Vita Life Sciences Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vita Life Sciences Ltd
ASX:VLS
|
Income from Continuing Operations
AU$9.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
30%
|
CAGR 10-Years
7%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Income from Continuing Operations
-AU$317.4m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Income from Continuing Operations
AU$157.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Income from Continuing Operations
-AU$14.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-24%
|
|
Probiotec Ltd
ASX:PBP
|
Income from Continuing Operations
AU$8.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Income from Continuing Operations
-AU$24.6m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vita Life Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
9.1m
AUD
Based on the financial report for Dec 31, 2023, Vita Life Sciences Ltd's Income from Continuing Operations amounts to 9.1m AUD.
What is Vita Life Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
7%
Over the last year, the Income from Continuing Operations growth was 24%. The average annual Income from Continuing Operations growth rates for Vita Life Sciences Ltd have been 16% over the past three years , 30% over the past five years , and 7% over the past ten years .